NRX Pharmaceuticals (NRXP) Assets (2017 - 2026)

NRX Pharmaceuticals (NRXP) has reported Assets for 10 consecutive years, with $34.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Assets rose 606.08% year-over-year to $34.2 million in Q2 2026; TTM through Jun 2026 was $34.2 million, a 606.08% increase from a year earlier, with the FY2025 full-year figure at $13.0 million, up 254.86% from the prior year.
• Assets was $34.2 million for Q2 2026 at NRX Pharmaceuticals, up from $11.9 million in the prior quarter.
• Over five years, Assets peaked at $43.6 million in Q1 2022 and troughed at $3.7 million in Q4 2024.
• A 5-year average of $16.2 million and a median of $13.0 million in 2023 frame the typical range for Assets.
• Across the five-year window, Assets jumped 623.34% in 2022 and sank 82.61% in 2024, its largest moves.
• Over 5 years, Assets stood at $25.8 million in 2022, then tumbled by 71.66% to $7.3 million in 2023, then sank by 50.09% to $3.7 million in 2024, then surged by 254.86% to $13.0 million in 2025, then surged by 163.66% to $34.2 million in 2026.
• The last three Assets figures came in at $34.2 million (Q2 2026), $11.9 million (Q1 2026), and $13.0 million (Q4 2025), per Business Quant data.